白细胞介素18在脓毒症诊断病情评估中的应用价值
摘要
目的
研究脓毒症患者血浆的IL-18表达水平以及IL-18表达水平与脓毒症临床严重程度、预后之间的关系。评价IL-18在脓毒症病情严重程度及预后判断中的应用价值。
方法
观察2008年7月至2009年6月之间郑州大学第一附属医院ICU的89例患者,其中病例组61例,对照组28例。收集患者入ICU时的生命体征(包括体温、呼吸、脉搏、血压)、血常规、肝功能、肾功能、凝血功能,并进行SOFA评分、APACHEⅡ评分和GCS评分。同时抽静脉血查C反应蛋白(CRP)、乳酸、血浆IL-18浓度。分析脓毒症患者IL-18表达水平与临床严重程度、预后之间的关系。’评价IL-18对脓毒症病情严重程度及预后判断的应用价值。
结果
病例组与对照组的生命体征,血常规、肝功能,肾功能,凝血功能和免疫功能比较均无统计学意义。病例组的SOFA评分高于对照组,有统计学意义(P<0.005)。病例组和对照组的APACHEⅡ评分、GCS评分之间无统计学差异。病例组的IL-18水平(P=0.008)、CRP(P<0.001)、乳酸(P=0.01)高于对照组。
脓毒性休克组患者的平均动脉压、纤维蛋白原和动脉血气的pH值低于非脓毒性休克组(P<0.05)。脓毒性休克患者的总胆红素、尿素氮高于非脓毒性休克组,均有统计学意义(P<0.05)。脓毒性休克组患者SOFA评分(P<0.001)、APACHEII评分(P=0.004)高于非脓毒性休克组；脓毒性休克组与非脓毒性休克组患者的GCS评分无统计学差异。脓毒性休克组患者的IL-18(P<0.001)、CRP(P=0.018)高于非脓毒性休克组；脓毒性休克组与非脓毒性休克组患者的血乳酸无统计学差异。
生存组的脓毒症患者纤维蛋白原高于死亡组(P=-0.004)；生存组的脓毒症患者总胆红素低于死亡组(P=0.001)。死亡组的脓毒症患者的SOFA评分(P <0.001)、APACHEⅡ评分(P=0.047)高于生存组。死亡组的脓毒症患者的GCS评分低于生存组(P=0.012)。死亡组脓毒症患者的IL-18(P=0.001)、CRP(P=0.001)高于生存组；死亡组与生存组脓毒症患者的血乳酸无统计学差异。
脓毒症的IL-18的受试者工作特征(ROC)曲线下面积为0.912[95%CI(0.770-1.000),P<0.001];CRP的ROC曲线下面积为0.850[95%CI(0.753-0.946),P<0.001]。
结论
IL-18可用于脓毒症患者严重程度及预后的判断。IL-18对脓毒症的诊断价值等同或不低于CRP。
Objective
To investigate the expressing levels of serum IL-18 in patients with sepsis, find the relationships between the levels of IL-18 and the severity, prognosis of sepsis, and then evaluate the value of IL-18 in the severity and prognostic of sepsis.
Methods
Eighty-nine patients enrolled in ICU of the First Affiliated Hospital of Zhengzhou University from July 2008 to June 2009 period were observed. They were divided into two groups:case group (n=61) and control group (n=28). The vital signs (including body temperature, respiration, pulse, blood pressure), blood routine, liver function, kidney function, blood coagulation were recorded. SOFA score, APACHEⅡscore and GCS score of patients were calculated. Serum IL-18, C-reactive protein (CRP) and lactate concentration were detected. The relationships between serum IL-18 and severity, prognosis of sepsis were statistical analyzed. The value of IL-18 in evaluation and prognosis in sepsis was assessed.
Results
There were no statistical difference of vital signs, blood routine, liver function, kidney function, blood coagulation between patients of the two groups. SOFA score of the case group was higher than that of the control group. There were no statistical difference of APACHE II score and GCS score between the two groups.IL-18 (P= 0.008) and CRP (P<0.001) of the case group were higher than that of the control group.
MAP, FIB and the pH value in the septic shock group were lower than that of the non-septic shock group (P<0.05). The TBIL, BUN of septic shock group were higher than that of the non-septic shock group (P<0.05). SOFA score (P<0.001), APACHE II score (P=0.004) of septic shock group were higher than that of the non-septic shock group.GCS score was no statistical difference between the two groups. The serum IL-18 levels (P<0.001) and CRP (P=0.018) in the septic shock group was higher than that of the non-septic shock group. The lactic acid was no statistical difference between two groups.
The FIB of the survival group was higher than that of the death group (P=0.004), TBIL of the survival group was lower than that of the death group (P=0.001).SOFA score (P<0.001), APACHE II score (P=0.047) of the death group were higher than that of the survival group. GCS of the death group was lower than that of the survival group (P=0.012). IL-18 (P=0.001) and CRP (P=0.001) of the death group were higher than that of the survival group.The lactic acid was no statistical difference between the two groups.
The ROC area under the curve of IL-18 in sepsis was 0.912 [95% CI (0.770-1.000), P<0.001], CRP was 0.850 [95% CI (0.753-0.946), P<0.001]. The value of IL-18 was higher than CRP in the diagnosis of sepsis.
Conclusions
IL-18 can be used for severity and prognosis of the patients with sepsis. The value of blood IL-18 was not lower than CRP in the diagnosis of sepsis.
研究脓毒症患者血浆的IL-18表达水平以及IL-18表达水平与脓毒症临床严重程度、预后之间的关系。评价IL-18在脓毒症病情严重程度及预后判断中的应用价值。
方法
观察2008年7月至2009年6月之间郑州大学第一附属医院ICU的89例患者,其中病例组61例,对照组28例。收集患者入ICU时的生命体征(包括体温、呼吸、脉搏、血压)、血常规、肝功能、肾功能、凝血功能,并进行SOFA评分、APACHEⅡ评分和GCS评分。同时抽静脉血查C反应蛋白(CRP)、乳酸、血浆IL-18浓度。分析脓毒症患者IL-18表达水平与临床严重程度、预后之间的关系。’评价IL-18对脓毒症病情严重程度及预后判断的应用价值。
结果
病例组与对照组的生命体征,血常规、肝功能,肾功能,凝血功能和免疫功能比较均无统计学意义。病例组的SOFA评分高于对照组,有统计学意义(P<0.005)。病例组和对照组的APACHEⅡ评分、GCS评分之间无统计学差异。病例组的IL-18水平(P=0.008)、CRP(P<0.001)、乳酸(P=0.01)高于对照组。
脓毒性休克组患者的平均动脉压、纤维蛋白原和动脉血气的pH值低于非脓毒性休克组(P<0.05)。脓毒性休克患者的总胆红素、尿素氮高于非脓毒性休克组,均有统计学意义(P<0.05)。脓毒性休克组患者SOFA评分(P<0.001)、APACHEII评分(P=0.004)高于非脓毒性休克组；脓毒性休克组与非脓毒性休克组患者的GCS评分无统计学差异。脓毒性休克组患者的IL-18(P<0.001)、CRP(P=0.018)高于非脓毒性休克组；脓毒性休克组与非脓毒性休克组患者的血乳酸无统计学差异。
生存组的脓毒症患者纤维蛋白原高于死亡组(P=-0.004)；生存组的脓毒症患者总胆红素低于死亡组(P=0.001)。死亡组的脓毒症患者的SOFA评分(P <0.001)、APACHEⅡ评分(P=0.047)高于生存组。死亡组的脓毒症患者的GCS评分低于生存组(P=0.012)。死亡组脓毒症患者的IL-18(P=0.001)、CRP(P=0.001)高于生存组；死亡组与生存组脓毒症患者的血乳酸无统计学差异。
脓毒症的IL-18的受试者工作特征(ROC)曲线下面积为0.912[95%CI(0.770-1.000),P<0.001];CRP的ROC曲线下面积为0.850[95%CI(0.753-0.946),P<0.001]。
结论
IL-18可用于脓毒症患者严重程度及预后的判断。IL-18对脓毒症的诊断价值等同或不低于CRP。
Objective
To investigate the expressing levels of serum IL-18 in patients with sepsis, find the relationships between the levels of IL-18 and the severity, prognosis of sepsis, and then evaluate the value of IL-18 in the severity and prognostic of sepsis.
Methods
Eighty-nine patients enrolled in ICU of the First Affiliated Hospital of Zhengzhou University from July 2008 to June 2009 period were observed. They were divided into two groups:case group (n=61) and control group (n=28). The vital signs (including body temperature, respiration, pulse, blood pressure), blood routine, liver function, kidney function, blood coagulation were recorded. SOFA score, APACHEⅡscore and GCS score of patients were calculated. Serum IL-18, C-reactive protein (CRP) and lactate concentration were detected. The relationships between serum IL-18 and severity, prognosis of sepsis were statistical analyzed. The value of IL-18 in evaluation and prognosis in sepsis was assessed.
Results
There were no statistical difference of vital signs, blood routine, liver function, kidney function, blood coagulation between patients of the two groups. SOFA score of the case group was higher than that of the control group. There were no statistical difference of APACHE II score and GCS score between the two groups.IL-18 (P= 0.008) and CRP (P<0.001) of the case group were higher than that of the control group.
MAP, FIB and the pH value in the septic shock group were lower than that of the non-septic shock group (P<0.05). The TBIL, BUN of septic shock group were higher than that of the non-septic shock group (P<0.05). SOFA score (P<0.001), APACHE II score (P=0.004) of septic shock group were higher than that of the non-septic shock group.GCS score was no statistical difference between the two groups. The serum IL-18 levels (P<0.001) and CRP (P=0.018) in the septic shock group was higher than that of the non-septic shock group. The lactic acid was no statistical difference between two groups.
The FIB of the survival group was higher than that of the death group (P=0.004), TBIL of the survival group was lower than that of the death group (P=0.001).SOFA score (P<0.001), APACHE II score (P=0.047) of the death group were higher than that of the survival group. GCS of the death group was lower than that of the survival group (P=0.012). IL-18 (P=0.001) and CRP (P=0.001) of the death group were higher than that of the survival group.The lactic acid was no statistical difference between the two groups.
The ROC area under the curve of IL-18 in sepsis was 0.912 [95% CI (0.770-1.000), P<0.001], CRP was 0.850 [95% CI (0.753-0.946), P<0.001]. The value of IL-18 was higher than CRP in the diagnosis of sepsis.
Conclusions
IL-18 can be used for severity and prognosis of the patients with sepsis. The value of blood IL-18 was not lower than CRP in the diagnosis of sepsis.
引文
[1]Hodgin KE, Moss M.The epidemiology of sepsis. Curr Pharm Des.2008,14(19):1833-1839.
[2]Martin GS, Mannino DM, Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med.2003,348(16):1546-1554.
[3]Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States:a trend analysis from 1993 to 2003. Crit Care Med.2007,35:1244-1250.
[4]Padkin A, Goldfrad C, Brady AR,et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003,31(9):2332-2338.
[5]Moerer O, Quintel M. Sepsis in adult patients-definitions, epidemiology and economic aspects. Internist,2009.50(7):788,790-798.
[6]Adrie C, Alberti C, Chaix-Couturier,et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity, infection site, and place of acquisition as determinants of workload and cost. J Crit care,2005,20(1):46-58.
[7]French CJ.The epidemiology of sepsis-is Australasia different? Crit care,2006,8(3): 219-222.
[8]Rezende E, Silva Junior JM, Isola AM, Campos EV, Amendola CP, Almeida SL. Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance. Clinics.2008,63:457-464.
[9]Cheng B, Xie G, Yao S,et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med.2007,35(11):2538-2546.
[10]American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992,101(6):1644-1655.
[11]Levy, Fink, Marshall, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med.2003,29(4):530-538.
[12]姚咏明,柴家科,林洪远.现代脓毒症理论与实践.科学出版社.2005.
[13]Milic M, Goranovic T, Holjevac JK.Correlation of APACHE II and SOFA scores with length of stay in various surgical intensive care units. Coll Antropol.2009,33(3):831-835.
[14]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[15]Khwannimit B, Bhurayanontachai R.The performance of customised APACHE Ⅱ and SAPS Ⅱ in predicting mortality of mixed critically ill patients in a Thai medical intensive care unit.Anaesth Intensive Care.2009 Sep;37(5):784-790.
[16]Koksal N, Harmanci R, Cetinkaya M,et al.Role of procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis.Turk J Pediatr.2007,49(1):21-29.
[17]Kocabas E, Sarikcioglu A, Aksaray N,et al. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. Turk J Pediatr.2007,49(1):7-20.
[18]Kurt AN, Aygun AD, Godekmerdan A,et al. Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediztors Inflamm.2007, 31397.
[19]Frink M, van Griensven M, Kobbe P,et al. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med.2009,17(1):49.
[20]Ucar B, Yildiz B, Aksit MA,et al. Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-lbeta levels in neonatal late-onset sepsis. Mediztors Inflamm. 2008,737141.
[21]Mussap M, Degrandi R, Cataldi L,et al. Biochemical markers for the early assessment of neonatal sepsis:the role of procalcitonin.J Chemother.2007,19 Suppl 2:35-38
[22]Wunder, Eichelbronner, Roewer. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis?Inflamm Res.2004,53(4):158-163.
[23]Genel F, Atlihan F, Ozsu E,et al.Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neonatal sepsis.J Infect.2010,60(3):224-228.
[24]Okamura H,Kauaguchi K,Shoji K,et al. High level induction of gramma interferon with various mitogens in mice pretreated with proplanl. Infect Immun,1982,38:440-443.
[25]Okamura H,Tlsutui H,Komatsu T.Cloning of a new cytokine that induce IFN-γ production by T cell.Nature,1995,378:88-91.
[26]Bazan JF,Timans JC,Kastelein RA. A newly defined interleukin-1. Nature.1996,379:591.
[27]Ushio S,Namba M,okura T.Cloning of the cDNA for human IFN-gamma-inducing factor,expression in E scherichia coli,and studies on the biologic activities of the protein.J Immunol.1996,156:4272-4279.
[28]Thompson SR, Humphries SE. Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun.2007,8(2):91-99.
[29]马强,杨楠,曹远宏.白细胞介素18与肾脏疾病.华南国防医学杂志.2009,23(1)：78-81.
[30]刘亚普.白细胞介素18的研究进展.中国医药指南.2008,6(13)：67-70.
[31]刘京衢,何忠杰,林宏远等.白细胞介素18的变化对创伤后脏器并发症的预警价值.中华创伤杂志.2004,20：530-532.
[32]Atkins GJ,Haynes DR,Geary SM,et al. Cloning and expression of human interleukin-18 gene in E.coli expression systems.J Immunol,2000,26 (2):653-661.
[33]Sugama S, Conti B.Interleukin-18 and stress. Brain Res Rev.2008,58(1):85-95.
[34]Tschoeke SK, Oberholzer A, Moldawer LL.Interleukin-18:a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med.2006,34(4):1225-1233.
[35]Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol.2003,73(2):213-224.
[36]Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol.2007,27(1):98-114.
[37]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[38]张平安,吴健民,李艳.湖北汉族人IL-18基因编码区105位点多态性及其血清含量相关性研究.检验医学.2006,21(1)：84-85.
[39]张瑞军,田志刚,魏海明等.重组人白细胞介素18的纯化及其生物学活性研究.中国免疫学杂志.2001,17(8)：411-415.
[40]Prasanta K,Sin-Hyeog, Miriam C,et al. A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology Letters 85 2000,85:65-/70.
[41]刘文强.白细胞介素18研究进展.动物医学进展.2009,30(4)：83-86.
[42]Jun-ichi Hirata, Joji Kotani,Michiko Aoyama,et al.A role for IL-18 in human neutrophil apoptosis.shock.2008,30(6):628-633.
[43]Giamila Fantuzzi, Nirmal K. Banda,Carla Guthridge,et al.Generation and characterization of mice transgenic for human IL-18-binding protein isoform. J Leukoc Biol.2003,74: 889-896;.
[44]Fernando A Bozza, Jorge I Salluh, Andre M Japiassu,et al.Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis. Critical Care.2007,11(2).
[45]Bryson K J, Wei X Q, Alexander J.Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania Mexicana in BALB/c mice.Microbe Infect,2008,10(7): 834-839.
[46]Marshall JD, Aste-Amezaga M, Chehimi SS,et al. Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90:15-21.
[47]Oberholzer A, Steckholzer U, Kurimoto M,et al. Interleukin-18 plasma levels are increased in patients with sepsis compared with severely injured patients. Shock.2001;16:411-414.
[48]王利峰,杨应明.白介素18与脑损伤.汕头大学医学院学报.2009,22(1)：58-62.
[49]Wereszczynska-Siemiatkowska U, Mroczko B, Siemiatkowski A.Serum profiles of interleukin-18 in different severity forms of human acute pancreatitis. Scand J Gastroenterol,2002,37 (9):1097-1102.
[50]Rau B, Baumgart K, Paszkowski AS, et al. Clinical relevance of caspase-1 activated cytokines in acute pancreatitis:high correlation of serum interleukin21 8 with pancreati c necrosis and systemic comp lications. Crit Care Med,2001,29 (8):1556-1562.
[51]袁柏思,朱人敏.白细胞介素-18在急性胰腺炎肝损伤中的作用.医学研究生学报.2007,20(10)：1104-1107.
[52]Arndt PG,Fantuzzi G,Abraham E,et al.Expression of interleukin-18 in the lung after endotoxemia or hemorrhage-induced acute lung injury.Am J Respir Cell Mol Biol.2000, 22:708-713.
[53]Meijing Wang,Troy A, Daniel R.Interleukin 18 in the heart. Shock.2008,30,(1):3-10.
[54]Mariana Vargas Furtado, Ana Paula Webber Rossini,Raquel Barth Campani,et al. Interleukin-18:an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up. Coronary Artery Disease.2009, 20:327-331.
[55]Sakao Y, Takeda K, Tsutsui H, et al. IL-18 deficientmice mice are resistant to endotoxin induced liver injury but highly suscep tible to endotoxic shock.Int Immunol,1999,11 (3): 471-474
[56]Akeda K, Tsutsui H, Yoshimoto T, et al. Defective NK. cell activity and TH1 response in IL-18 deficient mice. Immunity,1998,8 (3):383-390.
[57]Chirag R. Parikh, Edward Abraham, Marek Ancukiewicz,et al.Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. J Am Soc Nephrol,2005,16:3046-3052.
[58]Han WK,Bailly V,Abichardari R,et al. Kidney injury molecule 1:a novel biomarker for human renal proximal tuble injury.Kidney Int.2002,62:237-244.
[59]Wedeen RP,Udasinl,Fiedder N,et al.Urinary biomarker as indicators of renal disease. Ren Fail.1999,21:241-249.
[60]Pinsky P.C-reactive protein:a valuable marker of sepsis.Intensive Care Med.2002,28:235-243.
[61]Dilek Memis, Olcay Gursoy, Muhittin Tasdogan,et al. High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis. Journal of Clinical Anesthesia.2007,19:186-191.
[62]M. Khassawneh, Hayajneh, Kofahi, et al. Diagnostic Markers for Neonatal Sepsis: Comparing C-reactive Protein, Interleukin-6 and Immunoglobulin M. Scandinavian Journal of Immunology.2007,65:171-175.
[63]Vosylius S, Sipylaite J, Ivaskevicius J. Determinants of outcome in elderly patients admitted to the intensive care unit. Age Ageing.2005;34:157-62.
[64]白录军,郝万鹏.血乳酸测定的医学价值.现代检验医学杂志2007,22(1)：112-114.
[65]钟建勤,钟志民,高翔.动态监测血乳酸对危重病人在预后中价值.实用临床医学.2006,7(1)：36-37.
[66]Hirasawa H, Oda S, Nakamura M.Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol.2009,15(33):4132-4136.
[67]孙荣青,杨宏富.脓毒症患者入重症监护病房情况与Logistic回归分析.中国危重病急救医学,2009,21(9)：515-518.
[68]Curley G, Contreras MM, Nichol AD,et al. Hypercapnia and acidosis in sepsis:a double-edged sword?Anesthesiology.2010,112(2):462-472.
[69]刘晓伟,刘志.早期动脉血气分析对脓毒症患者预后的预测价值.中国全科医学.2009,22：381-385.
[70]崔金玲,任新生.脓毒症发生早期肝功能障碍的临床研究.岭南急诊医学杂志.2007,12(4)：251-254.
[71]叶文,王锦权,陶晓根.脓毒症与凝血功能紊乱.医学综述.2006,12(5)：296-298.
[72]胥志跃.脓毒症凝血系统功能障碍与预后关系的研究.医学临床研究.2007,24(6)：1030-1031.
[73]杨丽萍,姚咏明,盛志勇.脓毒症发病的炎症反应与免疫紊乱机制.感染、炎症、修复.2008,9(1)：48-50.
[1]Hodgin KE, Moss M.The epidemiology of sepsis. Curr Pharm Des.2008,14(19): 1833-1839.
[2]Martin GS, Mannino DM, Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med.2003,348(16):1546-1554.
[3]Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States:a trend analysis from 1993 to 2003. Crit Care Med.2007,35:1244-1250.
[4]Padkin A, Goldfrad C, Brady AR,et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003,31(9):2332-2338.
[5]Moerer O, Quintel M. Sepsis in adult patients-definitions, epidemiology and economic aspects. Internist.2009.50(7):788,790-798.
[6]Adrie C, Alberti C, Chaix-Couturier, et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity, infection site, and place of acquisition as determinants of workload and cost. J Crit Care.2005,20(1):46-58.
[7]French CJ.The epidemiology of sepsis-is Australasia different? Crit Care Resusc.2006, 8(3):219-222.
[8]Rezende E, Silva Junior JM, Isola AM, Campos EV, Amendola CP, Almeida SL. Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance. Clinics.2008,63:457-464.
[9]Cheng B, Xie G, Yao S,et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med.2007,35(11):2538-2546.
[10]American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Chest. 1992,101(6):1644-1655.
[11]Levy,Fink,Marshall, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med.2003,29(4):530-538.
[12]姚咏明,柴家科,林洪远.现代脓毒症理论与实践.科学出版社.2005.
[13]陆盛,崔乃强,傅强.肠源性内毒素血症的器官功能状态观察.中国中西医结合外科杂志,2009,15(2)：107-113.
[14]姚咏明,盛志勇.重视金黄色葡萄球菌脓毒症的研究.中华烧伤杂志.2000,16：75-77.
[15]姚咏明,盛志勇.金黄色葡萄球菌外毒素与脓毒症及多器官损害.中华创伤杂志.2004,20：711-714.
[16]姚咏明,盛志勇.脓毒症信号转导机制的现代认识.中国危重病急救医学.2003,15：3-6.
[17]孙荣青,杨宏富.弥漫性血管内凝血评分在脓毒症中的应用.中国危重病急救医学. 2009,21(8)：478-480.
[18]苏艳丽,王红,张淑文.脓毒症的凝血功能紊乱与抗凝治疗研究进展.中国危重病急救医学.2006,18(11)：698-702.
[19]姚咏明,刘辉,盛志勇.提高对神经-内分泌-免疫网络与创伤脓毒症的认识.中华创伤杂志.2006,22(8)：711-714.
[20]陈小路.基因多态性与脓毒症.国外医学遗传学分册.2004,27(6)：381-385.
[21]Okamura H, Kauaguchi K, Shoji K, et al. High level induction of gramma interferon with various mitogens in mice pretreated with proplanl. Infect Immun,1982,38:440-443.
[22]Okamura H,Tlsutui H,Komatsu T,Cloning of a new cytokine that induce IFN-γ production by T cell.Nature,1995,378:88-91.
[23]Bazan JF, Timans JC, Kastelein RA. A newly defined interleukin-1. Nature.1996,379:591.
[24]Ushio S, Namba M,Okura T,ea al.Cloning of the cDNA for human IFN-γ-inducing factor express in Eschenachia, and studies on the biologic activities of the protein. Immunol, 1996,156:4274-4279.
[25]Atkins GJ, Haynes DR, Geary SM, et al. Cloning and expression of human interleukin-18 gene in E. coli expression systems.J Immunol,2000,26 (2):653-661.
[26]Sugama S, Conti B.Interleukin-18 and stress. Brain Res Rev.2008,58(1):85-95.
[27]Tschoeke SK, Oberholzer A, Moldawer LL.Interleukin-18:a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med.2006,34(4):1225-1233.
[28]Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol.2003,73(2):213-224.
[29]Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol.2007,27(1):98-114.
[30]]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[31]张平安,吴健民,李艳.湖北汉族人IL-18基因编码区105位点多态性及其血清含量相关性研究.检验医学.2006,21(1)：84-85.
[32]张瑞军,田志刚,魏海明等.重组人白细胞介素18的纯化及其生物学活性研究.中国免疫学杂志.2001,17(8)：411-415.
[33]Prasanta K, Sin-Hyeog, Miriam C, et al. A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology Letters 85 2000,85:65-/70.
[34]刘文强.白细胞介素18研究进展.动物医学进展.2009,30(4)：83-86.
[35]Jun-ichi Hirata, Joji Kotani, Michiko Aoyama, et al. A role for IL-18 in human neutrophil apoptosis.shock.2008,30(6):628-633.
[36]Giamila Fantuzzi, Nirmal K. Banda,Carla Guthridge,et al.Generation and characterization of mice transgenic for human IL-18-binding protein isoform. J Leukoc Biol.2003,74: 889-896;.
[37]Fernando A Bozza, Jorge I Salluh, Andre M Japiassu,et al.Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis. Critical Care.2007,11(2).
[38]Bryson K J, Wei X Q, Alexander J.Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania Mexicana in BALB/c mice.Microbe Infect,2008,10(7):834-839.
[39]Marshall JD,Aste-Amezaga M, Chehimi SS,et al.Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90:15-21
[40]Oberholzer A, Steckholzer U, Kurimoto M,et al. Interleukin-18 plasma levels are increased in patients with sepsis compared with severely injured patients. Shock.2001; 16:411-414.
[41]刘京衢,何忠杰,林宏远等.白细胞介素18的变化对创伤后脏器并发症的预警价值.中华创伤杂志.2004,20：530-532.
[42]王利峰,杨应明.白介素18与脑损伤.汕头大学医学院学报.2009,22(1)：58-62.
[43]Wereszczynska-Siemiatkowska U, Mroczko B, Siemiatkowski A. Serum profiles of interleukin-18 in different severity forms of human acute pancreatitis. Scand J Gastroenterol,2002,37 (9):1097-1102.
[44]Rau B, Baumgart K, Paszkowski AS, et al. Clinical relevance of caspase-1 activated cytokines in acute pancreatitis:high correlation of serum interleukin-18 with pancreati c necrosis and systemic comp lications. Crit Care Med,2001,29 (8):1556-1562.
[45]袁柏思,朱人敏.白细胞介素-18在急性胰腺炎肝损伤中的作用.医学研究生学报.2007,20(10)：1104-1107.
[46]Arndt PG,Fantuzzi G,Abraham E,et al.Expression of interleukin-18 in the lung after endotoxemia or hemorrhage-induced acute lung injury. Am J Respir Cell Mol Biol.2000, 22:708-713.
[47]Meijing Wang, Troy A, Daniel R.Interleukin 18 in the heart. Shock.2008,30, (1):3-10.
[48]Mariana Vargas Furtado, Ana Paula Webber Rossini,Raquel Barth Campani,et al. Interleukin-18:an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up. Coronary Artery Disease.2009,20:327-331.
[49]Chirag R. Parikh, Edward Abraham, Marek Ancukiewicz,et al.Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. J Am Soc Nephrol,2005,16:3046-3052.
[50]Han WK,Bailly V,Abichardari R,et al. Kidney injury molecule 1:a novel biomarker for human renal proximal tuble injury.Kidney Int.2002,62:237-244.
[51]Wedeen RP,Udasinl,Fiedder N,et al.Urinary biomarker as indicators of renal disease.Ren Fail.1999,21:241-249.
[2]Martin GS, Mannino DM, Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med.2003,348(16):1546-1554.
[3]Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States:a trend analysis from 1993 to 2003. Crit Care Med.2007,35:1244-1250.
[4]Padkin A, Goldfrad C, Brady AR,et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003,31(9):2332-2338.
[5]Moerer O, Quintel M. Sepsis in adult patients-definitions, epidemiology and economic aspects. Internist,2009.50(7):788,790-798.
[6]Adrie C, Alberti C, Chaix-Couturier,et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity, infection site, and place of acquisition as determinants of workload and cost. J Crit care,2005,20(1):46-58.
[7]French CJ.The epidemiology of sepsis-is Australasia different? Crit care,2006,8(3): 219-222.
[8]Rezende E, Silva Junior JM, Isola AM, Campos EV, Amendola CP, Almeida SL. Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance. Clinics.2008,63:457-464.
[9]Cheng B, Xie G, Yao S,et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med.2007,35(11):2538-2546.
[10]American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992,101(6):1644-1655.
[11]Levy, Fink, Marshall, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med.2003,29(4):530-538.
[12]姚咏明,柴家科,林洪远.现代脓毒症理论与实践.科学出版社.2005.
[13]Milic M, Goranovic T, Holjevac JK.Correlation of APACHE II and SOFA scores with length of stay in various surgical intensive care units. Coll Antropol.2009,33(3):831-835.
[14]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[15]Khwannimit B, Bhurayanontachai R.The performance of customised APACHE Ⅱ and SAPS Ⅱ in predicting mortality of mixed critically ill patients in a Thai medical intensive care unit.Anaesth Intensive Care.2009 Sep;37(5):784-790.
[16]Koksal N, Harmanci R, Cetinkaya M,et al.Role of procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis.Turk J Pediatr.2007,49(1):21-29.
[17]Kocabas E, Sarikcioglu A, Aksaray N,et al. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. Turk J Pediatr.2007,49(1):7-20.
[18]Kurt AN, Aygun AD, Godekmerdan A,et al. Serum IL-1beta, IL-6, IL-8, and TNF-alpha levels in early diagnosis and management of neonatal sepsis. Mediztors Inflamm.2007, 31397.
[19]Frink M, van Griensven M, Kobbe P,et al. IL-6 predicts organ dysfunction and mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med.2009,17(1):49.
[20]Ucar B, Yildiz B, Aksit MA,et al. Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-lbeta levels in neonatal late-onset sepsis. Mediztors Inflamm. 2008,737141.
[21]Mussap M, Degrandi R, Cataldi L,et al. Biochemical markers for the early assessment of neonatal sepsis:the role of procalcitonin.J Chemother.2007,19 Suppl 2:35-38
[22]Wunder, Eichelbronner, Roewer. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis?Inflamm Res.2004,53(4):158-163.
[23]Genel F, Atlihan F, Ozsu E,et al.Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neonatal sepsis.J Infect.2010,60(3):224-228.
[24]Okamura H,Kauaguchi K,Shoji K,et al. High level induction of gramma interferon with various mitogens in mice pretreated with proplanl. Infect Immun,1982,38:440-443.
[25]Okamura H,Tlsutui H,Komatsu T.Cloning of a new cytokine that induce IFN-γ production by T cell.Nature,1995,378:88-91.
[26]Bazan JF,Timans JC,Kastelein RA. A newly defined interleukin-1. Nature.1996,379:591.
[27]Ushio S,Namba M,okura T.Cloning of the cDNA for human IFN-gamma-inducing factor,expression in E scherichia coli,and studies on the biologic activities of the protein.J Immunol.1996,156:4272-4279.
[28]Thompson SR, Humphries SE. Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun.2007,8(2):91-99.
[29]马强,杨楠,曹远宏.白细胞介素18与肾脏疾病.华南国防医学杂志.2009,23(1)：78-81.
[30]刘亚普.白细胞介素18的研究进展.中国医药指南.2008,6(13)：67-70.
[31]刘京衢,何忠杰,林宏远等.白细胞介素18的变化对创伤后脏器并发症的预警价值.中华创伤杂志.2004,20：530-532.
[32]Atkins GJ,Haynes DR,Geary SM,et al. Cloning and expression of human interleukin-18 gene in E.coli expression systems.J Immunol,2000,26 (2):653-661.
[33]Sugama S, Conti B.Interleukin-18 and stress. Brain Res Rev.2008,58(1):85-95.
[34]Tschoeke SK, Oberholzer A, Moldawer LL.Interleukin-18:a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med.2006,34(4):1225-1233.
[35]Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol.2003,73(2):213-224.
[36]Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol.2007,27(1):98-114.
[37]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[38]张平安,吴健民,李艳.湖北汉族人IL-18基因编码区105位点多态性及其血清含量相关性研究.检验医学.2006,21(1)：84-85.
[39]张瑞军,田志刚,魏海明等.重组人白细胞介素18的纯化及其生物学活性研究.中国免疫学杂志.2001,17(8)：411-415.
[40]Prasanta K,Sin-Hyeog, Miriam C,et al. A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology Letters 85 2000,85:65-/70.
[41]刘文强.白细胞介素18研究进展.动物医学进展.2009,30(4)：83-86.
[42]Jun-ichi Hirata, Joji Kotani,Michiko Aoyama,et al.A role for IL-18 in human neutrophil apoptosis.shock.2008,30(6):628-633.
[43]Giamila Fantuzzi, Nirmal K. Banda,Carla Guthridge,et al.Generation and characterization of mice transgenic for human IL-18-binding protein isoform. J Leukoc Biol.2003,74: 889-896;.
[44]Fernando A Bozza, Jorge I Salluh, Andre M Japiassu,et al.Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis. Critical Care.2007,11(2).
[45]Bryson K J, Wei X Q, Alexander J.Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania Mexicana in BALB/c mice.Microbe Infect,2008,10(7): 834-839.
[46]Marshall JD, Aste-Amezaga M, Chehimi SS,et al. Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90:15-21.
[47]Oberholzer A, Steckholzer U, Kurimoto M,et al. Interleukin-18 plasma levels are increased in patients with sepsis compared with severely injured patients. Shock.2001;16:411-414.
[48]王利峰,杨应明.白介素18与脑损伤.汕头大学医学院学报.2009,22(1)：58-62.
[49]Wereszczynska-Siemiatkowska U, Mroczko B, Siemiatkowski A.Serum profiles of interleukin-18 in different severity forms of human acute pancreatitis. Scand J Gastroenterol,2002,37 (9):1097-1102.
[50]Rau B, Baumgart K, Paszkowski AS, et al. Clinical relevance of caspase-1 activated cytokines in acute pancreatitis:high correlation of serum interleukin21 8 with pancreati c necrosis and systemic comp lications. Crit Care Med,2001,29 (8):1556-1562.
[51]袁柏思,朱人敏.白细胞介素-18在急性胰腺炎肝损伤中的作用.医学研究生学报.2007,20(10)：1104-1107.
[52]Arndt PG,Fantuzzi G,Abraham E,et al.Expression of interleukin-18 in the lung after endotoxemia or hemorrhage-induced acute lung injury.Am J Respir Cell Mol Biol.2000, 22:708-713.
[53]Meijing Wang,Troy A, Daniel R.Interleukin 18 in the heart. Shock.2008,30,(1):3-10.
[54]Mariana Vargas Furtado, Ana Paula Webber Rossini,Raquel Barth Campani,et al. Interleukin-18:an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up. Coronary Artery Disease.2009, 20:327-331.
[55]Sakao Y, Takeda K, Tsutsui H, et al. IL-18 deficientmice mice are resistant to endotoxin induced liver injury but highly suscep tible to endotoxic shock.Int Immunol,1999,11 (3): 471-474
[56]Akeda K, Tsutsui H, Yoshimoto T, et al. Defective NK. cell activity and TH1 response in IL-18 deficient mice. Immunity,1998,8 (3):383-390.
[57]Chirag R. Parikh, Edward Abraham, Marek Ancukiewicz,et al.Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. J Am Soc Nephrol,2005,16:3046-3052.
[58]Han WK,Bailly V,Abichardari R,et al. Kidney injury molecule 1:a novel biomarker for human renal proximal tuble injury.Kidney Int.2002,62:237-244.
[59]Wedeen RP,Udasinl,Fiedder N,et al.Urinary biomarker as indicators of renal disease. Ren Fail.1999,21:241-249.
[60]Pinsky P.C-reactive protein:a valuable marker of sepsis.Intensive Care Med.2002,28:235-243.
[61]Dilek Memis, Olcay Gursoy, Muhittin Tasdogan,et al. High C-reactive protein and low cholesterol levels are prognostic markers of survival in severe sepsis. Journal of Clinical Anesthesia.2007,19:186-191.
[62]M. Khassawneh, Hayajneh, Kofahi, et al. Diagnostic Markers for Neonatal Sepsis: Comparing C-reactive Protein, Interleukin-6 and Immunoglobulin M. Scandinavian Journal of Immunology.2007,65:171-175.
[63]Vosylius S, Sipylaite J, Ivaskevicius J. Determinants of outcome in elderly patients admitted to the intensive care unit. Age Ageing.2005;34:157-62.
[64]白录军,郝万鹏.血乳酸测定的医学价值.现代检验医学杂志2007,22(1)：112-114.
[65]钟建勤,钟志民,高翔.动态监测血乳酸对危重病人在预后中价值.实用临床医学.2006,7(1)：36-37.
[66]Hirasawa H, Oda S, Nakamura M.Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol.2009,15(33):4132-4136.
[67]孙荣青,杨宏富.脓毒症患者入重症监护病房情况与Logistic回归分析.中国危重病急救医学,2009,21(9)：515-518.
[68]Curley G, Contreras MM, Nichol AD,et al. Hypercapnia and acidosis in sepsis:a double-edged sword?Anesthesiology.2010,112(2):462-472.
[69]刘晓伟,刘志.早期动脉血气分析对脓毒症患者预后的预测价值.中国全科医学.2009,22：381-385.
[70]崔金玲,任新生.脓毒症发生早期肝功能障碍的临床研究.岭南急诊医学杂志.2007,12(4)：251-254.
[71]叶文,王锦权,陶晓根.脓毒症与凝血功能紊乱.医学综述.2006,12(5)：296-298.
[72]胥志跃.脓毒症凝血系统功能障碍与预后关系的研究.医学临床研究.2007,24(6)：1030-1031.
[73]杨丽萍,姚咏明,盛志勇.脓毒症发病的炎症反应与免疫紊乱机制.感染、炎症、修复.2008,9(1)：48-50.
[1]Hodgin KE, Moss M.The epidemiology of sepsis. Curr Pharm Des.2008,14(19): 1833-1839.
[2]Martin GS, Mannino DM, Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med.2003,348(16):1546-1554.
[3]Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States:a trend analysis from 1993 to 2003. Crit Care Med.2007,35:1244-1250.
[4]Padkin A, Goldfrad C, Brady AR,et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003,31(9):2332-2338.
[5]Moerer O, Quintel M. Sepsis in adult patients-definitions, epidemiology and economic aspects. Internist.2009.50(7):788,790-798.
[6]Adrie C, Alberti C, Chaix-Couturier, et al. Epidemiology and economic evaluation of severe sepsis in France:age, severity, infection site, and place of acquisition as determinants of workload and cost. J Crit Care.2005,20(1):46-58.
[7]French CJ.The epidemiology of sepsis-is Australasia different? Crit Care Resusc.2006, 8(3):219-222.
[8]Rezende E, Silva Junior JM, Isola AM, Campos EV, Amendola CP, Almeida SL. Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance. Clinics.2008,63:457-464.
[9]Cheng B, Xie G, Yao S,et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med.2007,35(11):2538-2546.
[10]American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Chest. 1992,101(6):1644-1655.
[11]Levy,Fink,Marshall, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med.2003,29(4):530-538.
[12]姚咏明,柴家科,林洪远.现代脓毒症理论与实践.科学出版社.2005.
[13]陆盛,崔乃强,傅强.肠源性内毒素血症的器官功能状态观察.中国中西医结合外科杂志,2009,15(2)：107-113.
[14]姚咏明,盛志勇.重视金黄色葡萄球菌脓毒症的研究.中华烧伤杂志.2000,16：75-77.
[15]姚咏明,盛志勇.金黄色葡萄球菌外毒素与脓毒症及多器官损害.中华创伤杂志.2004,20：711-714.
[16]姚咏明,盛志勇.脓毒症信号转导机制的现代认识.中国危重病急救医学.2003,15：3-6.
[17]孙荣青,杨宏富.弥漫性血管内凝血评分在脓毒症中的应用.中国危重病急救医学. 2009,21(8)：478-480.
[18]苏艳丽,王红,张淑文.脓毒症的凝血功能紊乱与抗凝治疗研究进展.中国危重病急救医学.2006,18(11)：698-702.
[19]姚咏明,刘辉,盛志勇.提高对神经-内分泌-免疫网络与创伤脓毒症的认识.中华创伤杂志.2006,22(8)：711-714.
[20]陈小路.基因多态性与脓毒症.国外医学遗传学分册.2004,27(6)：381-385.
[21]Okamura H, Kauaguchi K, Shoji K, et al. High level induction of gramma interferon with various mitogens in mice pretreated with proplanl. Infect Immun,1982,38:440-443.
[22]Okamura H,Tlsutui H,Komatsu T,Cloning of a new cytokine that induce IFN-γ production by T cell.Nature,1995,378:88-91.
[23]Bazan JF, Timans JC, Kastelein RA. A newly defined interleukin-1. Nature.1996,379:591.
[24]Ushio S, Namba M,Okura T,ea al.Cloning of the cDNA for human IFN-γ-inducing factor express in Eschenachia, and studies on the biologic activities of the protein. Immunol, 1996,156:4274-4279.
[25]Atkins GJ, Haynes DR, Geary SM, et al. Cloning and expression of human interleukin-18 gene in E. coli expression systems.J Immunol,2000,26 (2):653-661.
[26]Sugama S, Conti B.Interleukin-18 and stress. Brain Res Rev.2008,58(1):85-95.
[27]Tschoeke SK, Oberholzer A, Moldawer LL.Interleukin-18:a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med.2006,34(4):1225-1233.
[28]Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol.2003,73(2):213-224.
[29]Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol.2007,27(1):98-114.
[30]]Jastrow KM, Gonzalez EA, McGuire MF,et al. Early cytokine production risk stratifies trauma patients for multiple organ failure. J Am Coll Surg.2009,209(3):320-331.
[31]张平安,吴健民,李艳.湖北汉族人IL-18基因编码区105位点多态性及其血清含量相关性研究.检验医学.2006,21(1)：84-85.
[32]张瑞军,田志刚,魏海明等.重组人白细胞介素18的纯化及其生物学活性研究.中国免疫学杂志.2001,17(8)：411-415.
[33]Prasanta K, Sin-Hyeog, Miriam C, et al. A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology Letters 85 2000,85:65-/70.
[34]刘文强.白细胞介素18研究进展.动物医学进展.2009,30(4)：83-86.
[35]Jun-ichi Hirata, Joji Kotani, Michiko Aoyama, et al. A role for IL-18 in human neutrophil apoptosis.shock.2008,30(6):628-633.
[36]Giamila Fantuzzi, Nirmal K. Banda,Carla Guthridge,et al.Generation and characterization of mice transgenic for human IL-18-binding protein isoform. J Leukoc Biol.2003,74: 889-896;.
[37]Fernando A Bozza, Jorge I Salluh, Andre M Japiassu,et al.Cytokine profiles as markers of disease severity in sepsis:a multiplex analysis. Critical Care.2007,11(2).
[38]Bryson K J, Wei X Q, Alexander J.Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania Mexicana in BALB/c mice.Microbe Infect,2008,10(7):834-839.
[39]Marshall JD,Aste-Amezaga M, Chehimi SS,et al.Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90:15-21
[40]Oberholzer A, Steckholzer U, Kurimoto M,et al. Interleukin-18 plasma levels are increased in patients with sepsis compared with severely injured patients. Shock.2001; 16:411-414.
[41]刘京衢,何忠杰,林宏远等.白细胞介素18的变化对创伤后脏器并发症的预警价值.中华创伤杂志.2004,20：530-532.
[42]王利峰,杨应明.白介素18与脑损伤.汕头大学医学院学报.2009,22(1)：58-62.
[43]Wereszczynska-Siemiatkowska U, Mroczko B, Siemiatkowski A. Serum profiles of interleukin-18 in different severity forms of human acute pancreatitis. Scand J Gastroenterol,2002,37 (9):1097-1102.
[44]Rau B, Baumgart K, Paszkowski AS, et al. Clinical relevance of caspase-1 activated cytokines in acute pancreatitis:high correlation of serum interleukin-18 with pancreati c necrosis and systemic comp lications. Crit Care Med,2001,29 (8):1556-1562.
[45]袁柏思,朱人敏.白细胞介素-18在急性胰腺炎肝损伤中的作用.医学研究生学报.2007,20(10)：1104-1107.
[46]Arndt PG,Fantuzzi G,Abraham E,et al.Expression of interleukin-18 in the lung after endotoxemia or hemorrhage-induced acute lung injury. Am J Respir Cell Mol Biol.2000, 22:708-713.
[47]Meijing Wang, Troy A, Daniel R.Interleukin 18 in the heart. Shock.2008,30, (1):3-10.
[48]Mariana Vargas Furtado, Ana Paula Webber Rossini,Raquel Barth Campani,et al. Interleukin-18:an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up. Coronary Artery Disease.2009,20:327-331.
[49]Chirag R. Parikh, Edward Abraham, Marek Ancukiewicz,et al.Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. J Am Soc Nephrol,2005,16:3046-3052.
[50]Han WK,Bailly V,Abichardari R,et al. Kidney injury molecule 1:a novel biomarker for human renal proximal tuble injury.Kidney Int.2002,62:237-244.
[51]Wedeen RP,Udasinl,Fiedder N,et al.Urinary biomarker as indicators of renal disease.Ren Fail.1999,21:241-249.